TwinBeech Capital’s Castle Biosciences CSTL Stock Holding History

TwinBeech Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-32,866	Closed	-$721K	–	657
2022 Q2	$721K	Buy	+32,866	New	+$764K	0.03%	379

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TwinBeech Capital's CSTL Position: Q3 2022 in Review

TwinBeech Capital sold out of Castle Biosciences (CSTL) in Q3 2022, closing a stake of 32,866 shares — an estimated $721K sold.

TwinBeech Capital first reported a position in CSTL in Q2 2022 and held it in 1 quarter. The position peaked at $721K in Q2 2022. 157 funds tracked by Wall St. Rank hold CSTL as of Q3 2022.

TwinBeech Capital reported no remaining Castle Biosciences position as of Q3 2022 after selling out during the quarter.
TwinBeech Capital sold 32,866 Castle Biosciences shares in Q3 2022, an estimated $721K.
TwinBeech Capital first reported a position in Castle Biosciences in Q2 2022 and held it in 1 quarter.
TwinBeech Capital's Castle Biosciences position peaked at $721K in Q2 2022.
157 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2022.

Based on TwinBeech Capital's 13F filing for Q3 2022, filed 14 Nov 2022.